COVID-19 Pandemic: A Lesson for Antibiotic and Antiseptic Stewardship

Ronit Aloni-Grinstein^1, and Shahar Rotem¹

¹Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Box 19, 74100, Ness-Ziona

Cite this paper:
Ronit Aloni-Grinstein and Shahar Rotem. COVID-19 Pandemic: A Lesson for Antibiotic and Antiseptic Stewardship. American Journal of Public Health Research. 2021; 9(2):48-51. doi: 10.12691/ajphr-9-2-1

Abstract

Antibiotic resistance (AMR) is one of the major public health threats, with 700,000 annual deaths worldwide and an estimated 10 million per year by 2050. Efforts are made to establish antibiotic stewardship to minimize un-reversible AMR disasters. Yet, nowadays, when all medical and financial efforts are zoomed towards the COVID-19 pandemic, fundamental antibiotic and antiseptic stewardships are overlooked in favor of reducing the spread of the severe acute respiratory syndrome coronavirus (SAR-CoV-2), illness and death. On the other hand, public health measures, including social distance, reduction in international traveling, increased hygiene, and wearing facial masks are all means that may contribute to the prevention of the spreading of AMR bacteria. Hence, the COVID-19 pandemic maybe a worldwide turning point regarding AMR, for better or worse.

Keywords:
antibiotic stewardship antiseptic stewardship COVID-19 SAR-CoV-2 pandemic

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	WHO. Pneumonia of unknown cause-China. 2020; Available from: who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/.
[2]	Coronaviridae Study Group of the International Committee on Taxonomy of, V., The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 2020. 5(4): p. 536-544.
[3]	2020; Available from: worldometers.info/coronavirus/.
[4]	Dhama, K., et al., Coronavirus disease 2019-COVID-19. Clinical Microbiology Reviews, 2020. 33(4): p. e00028-20.
[5]	Wang, D., et al., Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020. 323(11): p. 1061-1069.
[6]	Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronaavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020. 395(10223): p. 507-513.
[7]	Keni, R., et al., COVID-19: Emergence, Spread, Possible Treatments and Global Burden. Front. Public Health, 2020.
[8]	Shen, C., et al., Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 2020. 323: p. 1582-1589.
[9]	Noy-Portat, T., et al., A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nature Communications, 2020. 11: p. 4303.
[10]	COVID-19-List results-ClinicalTrials.gov.; Available from: https://www.clinicaltrials.gov/ct2/results?cond=COVID- 19&term=&state=&city=7dist.
[11]	Maclntyre, C.R., et al., The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1)pdmo9. BMC Infect Dis., 2018. 18(1): p. 637.
[12]	Vaughn, V.M., et al., Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: A multi-hospital cohort study. Clin Infect Dis, 2020: p. ciaa1239.
[13]	Sepulveda, J., et al., Bacteremia and blood culture utilization during COVID-19 surge in New York city. Journal of Clinical Microbiology, 2020: p. 58e00875-20.
[14]	Lansbury, L., et al., Co-infection in people with COVID-19: a systemic review and meta-analysis. Journal of Infection and Chemotherapy., 2020.
[15]	Langford, B.J., et al., Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical Microbiology and Infection, 2020.
[16]	Hutter, B.D., et al., COVID-19: don't neglect antimicrobial stewardship principles! Clinical Microbiology and Infection, 2020.
[17]	Zhou, F., et al., Clinical course and risk facors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 2020. 395(10229): p. 1054-1062.
[18]	Cox, M., et al., Co-infection: potentiallly lethal and unexplored in COVID-19. The Lancet, 2020. 1.
[19]	Clancy, C.J. and M.H. Nguyen, Coronavirus disease 2019, Superinfections and antimicrobial development: What can we expect? Clin Infect Dis, 2020.
[20]	Clancy, C.J., D.J. Buehrle, and M.H. Nguyen, Pro: The COVID-19 pandemic will result in increase in animicrobial resistance rates. JAC Antimicrob Resist, 2020.
[21]	WHO, Clinical management of COVID-19 Interim guidance. 2020.
[22]	CDC. Community, Work and Schools: Cleaning and Disinfecting 2020; Available from: cdc.gov/coronavirus/2019-ncov/community/clean-disinfect/index/html.
[23]	Hora, P.I., et al., Increase use of quaternary ammonium compounds during the SARS-CoV-2 pandemic and beyond: considereation of environmetal implications. 2020.
[24]	EPA. List N tools: COVID-19 Disinfectants. 2020; Available from: cfpub.epa.gov/giwiz/disinfectants/index/cfm.
[25]	Wales, A.D. and R.H. Davis, Co-selection of resistance to antibiotics, biocides and heavy metals, and its relevance to foodborne pathogens. Antibiotics, 2015. 4: p. 567-604.
[26]	Nordmann, P., et al., The emerging NDM carbapenemases. Trends in Microbiology, 2011. 19(12): p. 588-595.
[27]	Castanheira, M., et al., Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the sentry antimicrobial surveillance program in 2014 and 2015. Antimicrob Agents Chemother., 2016. 60(22): p. 5623-4.
[28]	Rawson, T.M., et al., COVID-19 and the potential long-term impact on antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 2020.
[29]	Getahun, H., et al., Tackling antimicrobial resistance in the COVID-19 pandemic. Bulletin of the World Health Organization, 2020. 98: p. 442-442A.